Epiroc (OTC:EPOKY) Stock, Quote.Headers.trade-ideas

Epiroc is a global manufacturer of niche equipment and services used by mining and infrastructure customers. The company's products include hard rock drilling equipment and excavation technologies for underground and surface mining, as well as servicing and spare parts. Approximately 69% of group sales are from the aftermarket, which includes services and the sale of spare parts and consumables. Epiroc was spun out of Atlas Copco and listed as a stand-alone company on the Nasdaq Stockholm in June 2018.

Equities

News

Asset Sales

Markets

EPIROC AKTIEBOLAG SH AK A by EPIROC AKTIEBOLAG SHARE AK

EPIAF

EPOKY

Stanley Black &amp; Decker (NYSE: SWK) has agreed to divest its STANLEY Infrastructure division, which specializes in attachment and handheld hydraulic tools, to Epiroc AB (OTC: EPOKY) (OTC: 

Stanley Black &amp; Decker Streamlines Portfolio With $760M Infrastructure Sale To Epiroc, Targets Debt Reduction

Intraday Update

Movers

Trading Ideas

AAON

AAPL

ADBE

ADGS

ADSK

ADYEY

ADYYF

AEBZY

AFBA

AFGC

AGRX

AGYS

AIQUY

AKAM

ALLE

ALMFF

AMAT

ANSS

APMCF

APPF

ASAZY

ATLC

AUBN

AVGO

AZUL

BABYF

BAESF

BF-B

BMDPY

BUROF

BYDIF

CABO

CACI

CDPYF

CELH

CFBK

CFFA

CGEMY

CGEN

CGNX

CHGCY

CLNXF

CMWAY

COHU

COST

CPRT

CPWHF

CSLLY

CSPI

CVCO

CWCO

DASTY

DBOEF

DCMYY

DEAC

DNNGY

DOGEF

Stocks That Hit 52-Week Highs On Friday

ACGL

ACLLF

AGNC

ALLT

ALSWF

AMRU

ANCUF

ASGTF

ASNB

ATRC

ATZAF

AVMXF

AZPN

BAESY

BASI

BAYZF

BBSRF

BIOS

BKRKY

BMXMF

BRRZY

CABGY

CABJF

CAMT

CAPMF

CCXI

CFDB

CHGS

CHJI

CLGN

CLPBF

CNBI

CPIVF

CSII

CTXS

CYRLY

DBOEY

DREUF

ELEEF

ELRE

EMRAF

ENGIY

ENTG

EONGY

EPZM

Stocks That Hit 52-Week Highs On Tuesday

EPIROC AKTIEBOLAG U/ADR by Epiroc Aktiebolag

Epiroc AB

Jabil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) has outperformed the market over the past 20 years by 1.88% on an annualized basis producing an average annual return of 10.39%. Currently, Jabil has a market capitalization of $18.28 billion. 
Buying $1000 In JBL: If an investor had bought $1000 of JBL stock 20 years ago, it would be worth $7,183.40 today based on a price of $167.44 for JBL at the time of writing.
<h3>Jabil's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737489636_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Jabil Stock In The Last 20 Years

Financial giants have made a conspicuous bearish move on Biogen. Our analysis of options history for Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) revealed 8 unusual trades.
Delving into the details, we found 37% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $104,640, and 6 were calls, valued at $720,362.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $115.0 to $260.0 for Biogen during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Biogen options trades today is 238.14 with a total volume of 370.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Biogen's big money trades within a strike price range of $115.0 to $260.0 over the last 30 days.
<h3>Biogen Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737489634_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$43.4</td>
<td>$41.0</td>
<td>$41.0</td>
<td>$130.00</td>
<td>$328.0K</td>
<td align="right">604</td>
<td align="right">0</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$43.9</td>
<td>$40.8</td>
<td>$40.8</td>
<td>$130.00</td>
<td>$244.8K</td>
<td align="right">604</td>
<td align="right">155</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$7.6</td>
<td>$7.2</td>
<td>$7.2</td>
<td>$115.00</td>
<td>$54.7K</td>
<td align="right">354</td>
<td align="right">0</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$9.6</td>
<td>$9.4</td>
<td>$9.6</td>
<td>$130.00</td>
<td>$49.9K</td>
<td align="right">203</td>
<td align="right">2</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.7</td>
<td>$5.4</td>
<td>$5.7</td>
<td>$165.00</td>
<td>$47.8K</td>
<td align="right">290</td>
<td align="right">87</td>
</tr>
</tbody>
</table>

<h3>About Biogen</h3>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
After a thorough review of the options trading surrounding Biogen, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Biogen</h3>
<ul>
<li>With a volume of 525,457, the price of BIIB is up 0.65% at $141.47. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 21 days.</li>
</ul>
<h3>What Analysts Are Saying About Biogen</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $174.33333333333334.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Piper Sandler lowers its rating to Neutral with a new price target of $138. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on Biogen with a target price of $165. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Biogen, targeting a price of $220. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Biogen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

BIIB

Looking At Biogen's Recent Unusual Options Activity

Analysts' ratings for Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) over the last quarter vary from bullish to bearish, as provided by 10 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Tenable Holdings, presenting an average target of $47.7, a high estimate of $50.00, and a low estimate of $45.00. Observing a downward trend, the current average is 2.05% lower than the prior average price target of $48.70. 
<img src="https://www.benzinga.com/files/images/story/2025/1737489634_0_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Tenable Holdings among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$45.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$47.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tenable Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Tenable Holdings compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Tenable Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Tenable Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TENB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tenable Holdings analyst ratings.</a>
<h2>Discovering Tenable Holdings: A Closer Look</h2>
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
<h3>Tenable Holdings: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Tenable Holdings's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 12.68%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Tenable Holdings's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -4.06%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Tenable Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -2.4%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.57%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 1.01, Tenable Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

TENB

Analyst Expectations For Tenable Holdings's Future

Financial giants have made a conspicuous bearish move on Axon Enterprise. Our analysis of options history for Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) revealed 12 unusual trades.
Delving into the details, we found 16% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $166,800, and 8 were calls, valued at $503,194.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $220.0 to $700.0 for Axon Enterprise during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Axon Enterprise options trades today is 73.36 with a total volume of 152.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Axon Enterprise's big money trades within a strike price range of $220.0 to $700.0 over the last 30 days.
<h3>Axon Enterprise 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737489629_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$158.3</td>
<td>$155.1</td>
<td>$156.5</td>
<td>$500.00</td>
<td>$140.8K</td>
<td align="right">13</td>
<td align="right">9</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$124.9</td>
<td>$120.0</td>
<td>$122.58</td>
<td>$600.00</td>
<td>$122.5K</td>
<td align="right">84</td>
<td align="right">10</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$22.5</td>
<td>$20.3</td>
<td>$20.7</td>
<td>$610.00</td>
<td>$49.6K</td>
<td align="right">102</td>
<td align="right">5</td>
</tr>
<tr>
<td>AXON</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$95.8</td>
<td>$91.0</td>
<td>$93.5</td>
<td>$600.00</td>
<td>$46.7K</td>
<td align="right">30</td>
<td align="right">5</td>
</tr>
<tr>
<td>AXON</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$21.9</td>
<td>$19.6</td>
<td>$21.9</td>
<td>$600.00</td>
<td>$43.8K</td>
<td align="right">65</td>
<td align="right">58</td>
</tr>
</tbody>
</table>

<h3>About Axon Enterprise</h3>
Axon Enterprise Inc develops, manufactures, and sells conducted energy devices and cloud-based digital evidence management software designed for use by law enforcement, corrections, military forces, private security personnel, and private individuals for personal defense. The company operates in two segments: Taser and software &amp; sensors. Taser develops and sells CEDs used for protecting users and virtual reality training. Software and sensors manufacture fully integrated hardware and cloud-based software solutions such as body cameras, automated license plate reading, and digital evidence management systems. Axon delivers its products worldwide and derives the majority of its revenue from the software &amp; sensors segment and geographically from the United States.
After a thorough review of the options trading surrounding Axon Enterprise, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Axon Enterprise's Current Market Status</h3>
<ul>
<li>Trading volume stands at 275,330, with AXON's price up by 1.74%, positioned at $604.22.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 35 days.</li>
</ul>
<h3>What The Experts Say On Axon Enterprise</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $700.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from TD Cowen has revised its rating downward to Buy, adjusting the price target to $700. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Axon Enterprise, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

AXON

Decoding Axon Enterprise's Options Activity: What's the Big Picture?

Ratings for Brunswick (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BC#NYSE">BC</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $84.6, a high estimate of $100.00, and a low estimate of $64.00. Observing a downward trend, the current average is 7.64% lower than the prior average price target of $91.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1737489626_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Brunswick. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Megan Alexander</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$64.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Drew Crum</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$86.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$85.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Eric Wold</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$88.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Michael Albanese</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Brunswick. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Brunswick compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Brunswick's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Brunswick's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Brunswick analyst ratings.</a>
<h2>Get to Know Brunswick Better</h2>
Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns numerous Freedom Boat Club (shared ownership) locations as well as Boateka, which facilitates transactions in the used boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.
<h3>Financial Milestones: Brunswick's Journey</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Negative Revenue Trend: Examining Brunswick's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -20.1% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Brunswick's net margin excels beyond industry benchmarks, reaching 3.5%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Brunswick's ROE excels beyond industry benchmarks, reaching 2.2%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.72%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.34, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 5 Analyst Projections For Brunswick

Financial giants have made a conspicuous bullish move on Thermo Fisher Scientific. Our analysis of options history for Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) revealed 11 unusual trades.
Delving into the details, we found 45% of traders were bullish, while 27% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $129,030, and 8 were calls, valued at $437,834.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $300.0 to $600.0 for Thermo Fisher Scientific over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Thermo Fisher Scientific's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Thermo Fisher Scientific's whale activity within a strike price range from $300.0 to $600.0 in the last 30 days. 
<h3>Thermo Fisher Scientific Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737489623_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$18.2</td>
<td>$15.7</td>
<td>$16.1</td>
<td>$575.00</td>
<td>$83.7K</td>
<td align="right">0</td>
<td align="right">162</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$40.6</td>
<td>$35.6</td>
<td>$39.3</td>
<td>$540.00</td>
<td>$70.7K</td>
<td align="right">19</td>
<td align="right">18</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$133.5</td>
<td>$130.1</td>
<td>$133.5</td>
<td>$450.00</td>
<td>$66.7K</td>
<td align="right">20</td>
<td align="right">5</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$50.0</td>
<td>$45.1</td>
<td>$50.0</td>
<td>$590.00</td>
<td>$65.0K</td>
<td align="right">112</td>
<td align="right">17</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$16.7</td>
<td>$16.0</td>
<td>$16.09</td>
<td>$575.00</td>
<td>$59.3K</td>
<td align="right">0</td>
<td align="right">83</td>
</tr>
</tbody>
</table>

<h3>About Thermo Fisher Scientific</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
<h3>Present Market Standing of Thermo Fisher Scientific</h3>
<ul>
<li>Currently trading with a volume of 1,355,083, the TMO's price is up by 2.16%, now at $571.72. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 9 days.</li>
</ul>
<h3>Professional Analyst Ratings for Thermo Fisher Scientific</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $626.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Scotiabank downgraded its action to Sector Perform with a price target of $605. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Thermo Fisher Scientific, maintaining a target price of $647. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Thermo Fisher Scientific options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Thermo Fisher Scientific Unusual Options Activity For January 21

In the preceding three months, 4 analysts have released ratings for Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $95.5, along with a high estimate of $104.00 and a low estimate of $86.00. This upward trend is apparent, with the current average reflecting a 7.3% increase from the previous average price target of $89.00.
<img src="https://www.benzinga.com/files/images/story/2025/1737489611_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Ameren by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Durgesh Chopra</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$94.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>James Thalacker</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$98.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$86.00</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ameren. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Ameren compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ameren's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Ameren's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AEE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ameren analyst ratings.</a>
<h2>All You Need to Know About Ameren</h2>
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas in Missouri and Illinois. It serves more than 2.4 million electricity customers and more than 900,000 natural gas customers.
<h3>Ameren: Delving into Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining Ameren's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.49% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Utilities sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 20.98%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ameren's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.9% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.06%, the company showcases effective utilization of assets.
Debt Management: Ameren's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.54.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Ameren: Insights From 4 Analyst Reviews

WIIM

AXSM

Axsome Therapeutics shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.

Procter &amp; Gamble Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) will be reporting its second-quarter earnings on Wednesday. Wall Street expects $1.86 in EPS and $21.54 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=PG" target="_blank" rel="noreferrer noopener"> before market hours</a>.
The stock is up 9.29% over the past year, down 2.64% YTD.
Let&#8217;s look at what the charts indicate for Procter &amp; Gamble stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/trading-ideas/dividends/24/12/42743301/dogs-of-the-dow-top-10-high-yield-stocks-offering-dividends-up-to-6-8-in-2025">Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025</a>
<h2 class="wp-block-heading">PG Stock Chart Bearish Ahead Of Q2 Earnings</h2>
PG stock is showing a strongly bearish trend, with its price of $161.59 trading below its five, 20 and 50-day exponential moving averages.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="629" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21132711/Screenshot-2025-01-21-at-11.45.16-PM.png" alt="" class="wp-image-743346" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21132711/Screenshot-2025-01-21-at-11.45.16-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21132711/Screenshot-2025-01-21-at-11.45.16-PM-300x232.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012125&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
While slight buying pressure is evident as the eight-day SMA (simple moving average) at $160.26 signals a bullish move, the broader setup remains bearish, with the 20-day SMA at $164.19, 50-day SMA at $168.68, and 200-day SMA at $167.60 all above the current price. 
The MACD (moving average convergence/divergence) indicator at a negative 2.76 reinforces downside momentum, while the RSI (relative strength index) at 38.61 suggests the stock is nearing oversold territory but not there yet.
<h2 class="wp-block-heading">Procter &amp; Gamble Analysts See 4% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/PG/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Procter &amp; Gamble stock stands at a Buy currently with a price target of $175.42. The latest analyst ratings from Barclays, Stifel, and UBS give PG stock an average price target of $168.33, implying a 4.01% upside.
PG Price Action: Procter &amp; Gamble stock was trading at $161.63 at the time of publication.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43074340/jim-cramers-market-outlook-strong-earnings-trump-inauguration-and-whats-next-for-investors">Jim Cramer&#8217;s Market Outlook: Strong Earnings, Trump Inauguration, and What&#8217;s Next for Investors</a></li>
</ul>

Earnings

Technicals

Previews

P&G's Chart Shows Bearish Signs – Is Q2 Earnings The Turning Point?

The 2028 presidential election is over 1,000 days away and President Donald Trump <a href="https://www.benzinga.com/government/regulations/25/01/43085323/trump-sworn-in-as-47th-president-declares-golden-age-of-america-begins-right-now">just took office</a>, but that hasn&#8217;t stopped sportsbooks and prediction markets from taking an early look at the election betting odds.
What Happened: From Bet365, here are the current betting odds on who will emerge as a top candidate, as reported by <a href="https://www.covers.com/politics/us-election-betting-odds">Covers</a>:
<ul>
<li>J.D. Vance (Republican): +250</li>
<li>Gavin Newsom (Democrat): +1,000</li>
<li>Josh Shapiro (Democrat): +1,000</li>
<li>Pete Buttigieg (Democrat): +1,400</li>
<li>Michelle Obama (Democrat): +1,600</li>
<li>Gretchen Whitmer (Democrat): +1,600</li>
<li>Vivek Ramaswamy (Republican): +1,600</li>
<li>Donald Trump Jr. (Republican): +1,600</li>
<li>Ron DeSantis (Republican): +2,000</li>
<li>Tucker Carlson (Republican): +2,000</li>
<li>Tulsi Gabbard (Republican): +2,000</li>
<li>Kamala Harris (Democrat): +2,000</li>
</ul>
Outside of those figures, other notable names include Nikki Haley (Republican) at +4,000 and Hillary Clinton (Democrat) at +5,000.
Here are the odds from BetMGM, which is a unit of MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>), as <a href="https://www.actionnetwork.com/politics/2028-united-states-presidential-election-odds-potential-candidates-include-jd-vance-michelle-obama-more">shared </a>by Action Network:
<ul>
<li>J.D Vance: +275</li>
<li>Gavin Newsom: +650</li>
<li>Josh Shapiro: +800</li>
<li>Michelle Obama: +800</li>
<li>Ron DeSantis: +1,000</li>
<li>Pete Buttigieg: +1,400</li>
<li>Vivek Ramaswamy: +1,400</li>
<li>Gretchen Whitmer: +1,600</li>
<li>Ivanka Trump (Republican): +2,000</li>
<li>Marco Rubio (Republican): +2,000</li>
<li>Alexandria Ocasio-Cortez (Democrat): +2,500</li>
<li>Andy Beshear (Democrat): ++2,500</li>
<li>Kristi Noem (Republican): +2,500</li>
<li>Nikki Haley: +2,500</li>
<li>Tucker Carlson: +2,500</li>
</ul>
BetMGM UK also has other notable names like Robert F. Kennedy Jr. (+3,300), Donald Trump Jr. (+3,300) and Hillary Clinton (+5,000) listed further down the odds. Harris is notably missing in the current BetMGM UK odds, but that may change if she ever makes her future intentions clear. 
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent012125">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Prediction Markets: Kalshi, which is legal to U.S. bettors has several betting markets open for 2028, including the winning <a href="https://kalshi.com/markets/kxpresparty/party-winning-presidency">party </a>with Republicans at 49% and Democrats at 51%.
Here are the betting <a href="https://kalshi.com/markets/kxpresnomr/republican-primary-winner">odds </a>on Kalshi for the GOP nominee for the 2028 election, with <a href="https://www.benzinga.com/general/sports-betting/24/11/41830883/2028-election-betting-odds-where-do-j-d-vance-michelle-obama-mark-cuban-ron-desantis-kamal">odds from November</a> in parentheses:
<ul>
<li>J.D. Vance: 44% (57%)</li>
<li>Vivek Ramaswamy: 7% (4%)</li>
<li>Donald Trump: 7% (4%)</li>
<li>Ron DeSantis: 6% (6%)</li>
<li>Donald Trump Jr.: 6% (7%)</li>
<li>Marco Rubio: 5% (Under 4%)</li>
</ul>
The 22nd&nbsp;Amendment currently would keep Trump from serving more than two terms in the White House, but he&#8217;s included in Kalshi&#8217;s odds here.
Here are the betting&nbsp;<a href="https://kalshi.com/markets/kxpresnomd/democratic-primary-winner" target="_blank" rel="noreferrer noopener">odds&nbsp;</a>on Kalshi for the Democrat Party nominee for the 2028 election with odds from November in parentheses:
<ul>
<li>Gavin Newsom: 14% (16%)</li>
<li>Josh Shapiro: 13% (16%)</li>
<li>Alexandria Ocasio-Cortez: 8% (7%)</li>
<li>Pete Buttigieg: 8% (11%)</li>
<li>Wes Moore: 7% (9%)</li>
<li>Michelle Obama: 7% (6%</li>
<li>Gretchen Whitmer: 6% (14%)</li>
<li>Kamala Harris: 5% (2%)</li>
</ul>
Why It Matters: The 2024 presidential election could go down as the political event that changed prediction markets forever. <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41694948/trump-polymarket-whale-has-30m-bet-on-former-president-winning-2024-election-my-intent-is-">Billions of dollars were</a> wagered on Polymarket and CFTC-regulated market Kalshi.
Polymarket, which <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41694948/trump-polymarket-whale-has-30m-bet-on-former-president-winning-2024-election-my-intent-is-" target="_blank" rel="noreferrer noopener">had many prediction markets</a> for the 2024 election, does not currently offer 2028 markets. The decentralized platform allows users to deposit funds using USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) via the Polygon (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">POL</a>) network or directly from a crypto account with Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>). The platform will be closely watched in the coming months to see who takes the early lead in 2028 election betting.
No candidate has officially declared their intentions to run for president on Nov. 7, 2028. With Trump unable to run for president again, barring a change to the U.S. Constitution, it is likely that Vance would be the frontrunner to win the Republican Party nomination.
The betting odds and prediction markets also list Donald Trump Jr. and Ivanka Trump suggesting that someone in the Trump family could seek to continue their father's legacy.
For the Democratic Party, things could look different in 2028 depending on if Harris, who lost the 2024 election, decides to run again. Harris was the party's nominee after Joe Biden stepped <a href="https://www.benzinga.com/general/politics/24/07/39874057/biden-drops-out-of-2024-race-in-bombshell-announcement-it-has-been-the-greatest-honor-of-my-life">down from the race</a>.
Along with prediction markets, Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) got in on the fun <a href="https://www.benzinga.com/general/sports-betting/24/11/41719799/robinhood-passes-100-million-2024-election-contracts-do-users-favor-trump-or-harris-on-sto">with election contracts</a> offered on the 2024 election winner. After a successful initial venture into politics, Robinhood hinted it could have<a href="https://www.benzinga.com/general/sports-betting/24/12/42345211/robinhood-ceo-vlad-tenev-says-sports-betting-comments-taken-a-little-bit-out-of-context-but-he-also-wouldnt-rule-it-out"> more sports betting </a>options available in the future.
Sportsbook giant DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) could also have election betting in the future, based <a href="https://www.benzinga.com/general/sports-betting/23/05/32244769/exclusive-draftkings-benefits-from-non-nfl-sports-growth-eyes-horse-racing-and-election-be">on past comments </a>from CEO Jason Robins. DraftKings offered 2024 election betting in Canada.
Robins previously told Benzinga the company is continuing to work with regulators to get election betting approved for states that offer legalized betting. With the election more than three years away, there is a chance that the U.S. could have more legalized betting options for political outcomes the next time a presidential race is decided. Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/01/43041374/exclusive-how-high-will-sp-500-go-under-donald-trump-in-2025-readers-are-optimistic-26-say-this">EXCLUSIVE: How High Will S&amp;P 500 Go Under Donald Trump In 2025? Readers Are Optimistic, 26% Say This…</a></li>
</ul>
Image: Shutterstock

Sports Betting

Politics

$ETH

$POL

$USDC

DKNG

HOOD

2028 Election Betting Odds: Where Do J.D. Vance, Kamala Harris, Michelle Obama, Donald Trump Jr. Rank?

There is a story I love telling about one of history&#8217;s greatest value investors. She was a woman who made her fortune by following two simple principles that are just as relevant today as they were in the 19th century.
I'm talking about Hetty Green, the infamous &#8220;Witch of Wall Street.&#8221;
Born in 1834 in New Bedford, Massachusetts, Hetty learned the art of finance at her father&#8217;s knee while most girls her age studied needlepoint. By age thirteen, she was keeping the books for her family&#8217;s whaling business. Her real education, however, came from her grandfather, who taught her to read stock tables and understand the intricacies of commerce and trade.
Hetty left us with two golden rules that every investor should tattoo on their forehead.
The first one you'll easily recognize: &#8220;I buy when things are low and no one wants them. I keep them until they go up and people are crazy to get them.&#8221;
And this crucial addition:
&#8220;There is no great secret in fortune making. All you do is buy cheap and sell dear, act with thrift and shrewdness, and be persistent.&#8221;
Is it simple? Yes. Is it easy to execute? Absolutely not.
<h2 class="wp-block-heading">The Green Method: A Template for Success</h2>
Hetty&#8217;s approach was beautifully straightforward. In good times, she was a lender, primarily focusing on well collateralized real estate deals. When markets turned chaotic, she became an aggressive buyer, scooping up distressed assets that others would not touch with a ten-foot pole.
In the 1890s, Texas was experiencing one of its worst droughts, sending land prices plummeting. While most investors were paralyzed with fear, Green recognized an extraordinary opportunity. She systematically acquired vast tracts of Texas real estate at deeply discounted prices. Her philosophy about investing &#8220;when blood was running in the streets&#8221; would later be echoed by Warren Buffett; this serves as a testament to the timeless nature of her investment wisdom.
Despite being unfairly labeled as a loan shark by her critics, Green&#8217;s lending practices demonstrated sophisticated risk management. She insisted on securing every loan with tangible collateral, typically real estate or other hard assets. There is an illuminating story about her approach involving a church seeking emergency funding. When she demanded the church&#8217;s deed as collateral, someone questioned whether she would actually foreclose on a religious institution. Her response was characteristically direct: &#8220;I would foreclose on a church, dearie. Business is business.&#8221;
This episode beautifully illustrates several enduring investment principles that remain valuable today. First, Green understood the paramount importance of maintaining substantial liquid reserves. This allowed her to act decisively when genuine bargains appeared; this strategy remains just as crucial now as it was then.
She also grasped something that many modern investors overlook: the fundamental value of hard assets. In an era of increasingly complex financial instruments, her insistence on tangible collateral seems remarkably prescient. She knew that real assets retain intrinsic value regardless of market conditions.
Perhaps most importantly, Green mastered the psychological aspect of investing. She developed the emotional discipline to invest counter cyclically, buying assets when fear drove others to sell. This requires a kind of temperamental advantage that is rare in any era: the ability to remain rational when others are gripped by panic.
Despite her considerable wealth, Green maintained strict financial discipline, controlling expenses with remarkable vigor. This combination of frugality and intelligent capital allocation enabled her to compound her wealth consistently over time.
She also demonstrated remarkable patience, understanding that the best investment opportunities often require waiting through long periods of market irrationality. This quality, the ability to wait for the right opportunity rather than forcing action, separates truly great investors from the merely good ones.
These principles were not just effective in the 1890s; they are the same foundational concepts that create lasting wealth in any era.
[Unlock Insider-Level Market Alerts, With Benzinga Pro]
<h2 class="wp-block-heading">Fast Forward to Today&#8217;s Market</h2>
Now, let us apply Hetty&#8217;s wisdom to our current situation. The market is trading at roughly 30 times trailing earnings and 21 to 22 times projected earnings; these are historically high levels that would make Hetty Green raise an eyebrow. The CAPE ratio sits at 38, and we are looking at a market cap to GDP ratio of 200%; this represents one of the highest levels ever seen in U.S. history.
Here is the crucial point: The United States represents 4% of global population, 25% of market GDP, and an astounding 70% of global market cap. If that does not scream &#8220;expensive,&#8221; I do not know what does.
<h2 class="wp-block-heading">What Would Hetty Do?</h2>
Following Hetty&#8217;s playbook in today&#8217;s market means being a selective lender. At Benzinga Yield Report, we are focusing on:
<ul>
<li>Carefully selected Business Development Companies</li>
<li>Commercial real estate mortgage REITs</li>
<li>Residential mortgage REITs</li>
</ul>
Consider the Simplify Mortgage Backed Securities ETF (MTBA) for those looking for an even lower-risk option. With a current yield of about 6% and backed by agency mortgages, it offers an attractive risk-reward profile in a market where 60% of mortgages are below 4%.
<h2 class="wp-block-heading">The Bottom Line</h2>
The next decade might not deliver the returns we have seen in the past fifteen years. We could see a melt up followed by a crash, a sudden collapse offering tremendous opportunities, or the nightmare scenario: a long, grinding sideways market that tests investors&#8217; patience.
But remember Hetty&#8217;s approach: Be a lender when assets are expensive, and be ready to buy aggressively when everything goes on sale. It is not just about making money; it is about being positioned to take advantage when others are running scared.
Hetty Green may have been known as the Witch of Wall Street, living on oatmeal heated on radiators and wearing the same dress until it fell apart, but she died one of the richest women in the world. Her strategy of lending in good times and buying in bad times built generational wealth that even today&#8217;s investors can learn from.
The market might be expensive now, but somewhere down the road, our Hetty Green moment will come.
The question remains: Will we be ready to seize it?
With Benzinga Pro, you'll get access to exclusive market alerts that have led to big wins, like 270% gains on BLPH. Experience what it's like to have a trading floor in your pocket, all for FREE for two weeks. <a href="https://www.benzinga.com/pro/checkout/benzinga-pro-essential-trial-2024/?utm_source=WebRD-0122&amp;el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}">Get started now.</a>
Image Via Shutterstock

Opinion

The "Witch of Wall Street's" Timeless Investment Wisdom

LEGN

Legend Biotech shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.

<a href="https://x.com/rumblevideo/status/1881790818434109579" title="https://x.com/rumblevideo/status/1881790818434109579">https://x.com/rumblevideo/status/1881790818434109579</a>

Guidance

Rumble Posted On X: Rumble posted an all time record for average concurrent creator livestreams, surpassing our last record on Dec 6th and election night.

CAAP

Corporacion America Airports shares are trading higher after the company provided updates for total December passenger traffic.

Goldman Sachs analyst Richard Ramsden reiterated the Neutral rating on U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>), <a target="_blank" href="https://www.benzinga.com/quote/USB/analyst-ratings" rel="noreferrer noopener">lowering the price forecast to $49.</a>
Last week, the company reported&nbsp;fourth quarter&nbsp;adjusted earnings per share of $1.07, beating the street view of $1.05.
Quarterly sales of $6.98 billion marginally missed the analyst <a target="_blank" href="https://www.benzinga.com/25/01/43028258/us-bancorp-beats-q4-eps-estimates-return-on-tangible-equity-hits-183-as-ceo-emphasizes-resilience-amid-challenges" rel="noreferrer noopener">consensus estimate of $6.996 billion</a>.
The analyst projects the company&#8217;s net interest income to grow 3% year-over-year in 2025, which is lower than peers due to limited upside from fixed asset repricing.
However, Ramsden sees an accelerated loan growth in the second half of 2025, potentially boosting&nbsp;&nbsp;net interest income.
U.S. Bancorp&#8217;s CET1 ratio stands at 10.6%, with an estimated adjusted ratio of 8.6%, above the regulatory minimum of 7.6%, but still below the 10% target for Category II banks, the analyst writes.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/travel/25/01/43107336/jetblue-to-bring-venmo-onboard-for-online-bookings-details" rel="noreferrer noopener">JetBlue To Bring Venmo Onboard For Online Bookings: Details</a>
The company is expected to maintain a cautious approach to share buybacks, balancing capital distribution with the need for further capital build-up as it moves toward becoming a Category II bank by 2027.
The analyst&#8217;s 2025 and 2026 earnings per share (EPS) estimates remain largely unchanged, with a new 2027 EPS estimate of $5.35 and an unchanged P/E target of 11.5x for 2025.
However, Ramsden forecasts a few downside risks for the stock, which include slower revenue growth than forecast, lower cost savings from the integration of Union Bank, a greater increase in credit losses, and the risk of higher regulatory, IT, and compliance costs.
Price Action: USB shares are trading higher by 1.63% to $49.15 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/travel/25/01/43062173/bank-of-america-delta-united-to-lead-airline-industry-in-2025" target="_blank" rel="noreferrer noopener">Bank Of America: Delta, United To Lead Airline Industry In 2025</a></li>
</ul>
Photo by Ground Picture on Shutterstock.

Analyst Color

Price Target

Reiteration

General

U.S. Bancorp May See 3% Net Interest Income Growth in 2025, But Regulatory Capital Goals May Limit Share Buyback Pace: Analyst

<a href="https://valor.globo.com/empresas/noticia/2025/01/21/gigantes-globais-da-aviacao-querem-fatia-da-gol-de-olho-em-guarulhos-e-galeao.ghtml" title="https://valor.globo.com/empresas/noticia/2025/01/21/gigantes-globais-da-aviacao-querem-fatia-da-gol-de-olho-em-guarulhos-e-galeao.ghtml">https://valor.globo.com/empresas/noticia/2025/01/21/gigantes-globais-da-aviacao-querem-fatia-da-gol-de-olho-em-guarulhos-e-galeao.ghtml</a>

Valor Economico Reported Airlines Including United Airlines, American Airlines, Lufthansa, Air France-KLM In Talks To Acquire Stake In Brazil's Gol

Wall Street had a <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43068335/wall-street-rallies-as-inflation-fears-recede-banks-smash-earnings-bitcoin-reclaims-100000-this-week-in-the-markets">strong rally last week</a>, driven by a combination of easing core inflation, a Gaza ceasefire agreement and robust bank earnings. Major indices closed the week with impressive gains: the S&amp;P 500 was up 2.9%, the Dow Jones climbed 3.7% and the Nasdaq Composite advanced 2.4%.
Needless to say, several ETFs also cashed in on the upbeat market environment. Here are five ETFs that ended the week on Jan. 17 on a happy note.
Direxion Daily Real Estate Bull 3X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRN#NYSE">DRN</a>) Weekly gain: 15.25% Focus: Tracks U.S. REITs, offering a short-term view of the U.S. real estate sector. Expense Ratio: 1.01%
<h1 class="wp-block-heading">YieldMax MSTR Option Income Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSTY#NYSE">MSTY</a>)</h1>
Weekly Gain: 13.28% Focus: Tracks MicroStrategy's share price while generating income. Expense Ratio: 0.99% 
<h1 class="wp-block-heading">First Trust SkyBridge Crypto Industry &amp; Digital Economy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRPT#NYSE">CRPT</a>)</h1>
Weekly Gain: 13.20% Focus: Invests in crypto-related industries, with Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) as its top holding. Expense Ratio: 0.85% 
<h1 class="wp-block-heading">ProShares Ultra Industrials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UXI#NYSE">UXI</a>)</h1>
Weekly Gain: 11.3% Focus: Tracks the Dow Jones U.S. Industrials Index. General Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) and Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) are among its top holdings. Expense Ratio: 0.75% 
<h1 class="wp-block-heading">ProShares Ultra SmallCap600 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAA#NYSE">SAA</a>)</h1>
Weekly Gain: 8.9% Focus: Mirrors the S&amp;P SmallCap 600 Index and includes stocks of companies like Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) and Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) in its portfolio. Expense Ratio: 0.75%
<h1 class="wp-block-heading">What Drove Markets</h1>
While December&#8217;s annual inflation ticked up slightly to 2.9%, the increase came within market expectations, which served as a hope for a potentially dovish stance from the Federal Reserve. Retail sales rose by 0.4% in December, below the expected 0.6%, further fanning speculation of slower rate hikes.
See Also: <a href="https://www.benzinga.com/news/global/25/01/43076662/three-hostages-cross-into-israeli-territory-after-471-days-as-ceasefire-begins">Three Hostages Cross Into Israeli Territory After 471 Days as Ceasefire Begins</a>
In geopolitical news, the <a href="https://www.benzinga.com/news/global/25/01/43017362/israel-hamas-agree-to-ceasefire-deal-including-hostage-release-biden-confirms">ceasefire between Israel and Hamas</a> brought some relief to global markets, reducing risks of regional disruptions. Additionally, positive earnings from major banks underlined the resilience of financial institutions, adding to market optimism.
Furthermore, Bitcoin&#8217;s standout performance last week sent the cryptocurrency 9% northward, marking a solid recovery. Inevitably, this rally lifted securities linked to Bitcoin, including MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), which saw its shares jump 28%, and Coinbase Global, up 20%.
Again, major banks inaugurated the fourth-quarter 2024 earnings season with strong results, <a href="https://www.benzinga.com/topic/banks">pushing bank stocks up.</a>
See Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43105356/meme-coin-supercycle-dogecoin-trump-bonk-futures-etf-applications-filed">Meme Coin Supercycle? Dogecoin, Trump, Bonk Futures ETF Applications Filed</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

ETFs

COIN

CRPT

Direxion Daily Real Estate Bull 3x Shares

MSTR

Tidal Trust II YieldMax MSTR Option Income Strategy ETF

MSTY

Wall Street Rally Sparks ETF Gains: Top 5 Performers Of Last Week

In states where both medical and recreational marijuana are legal, patients are filling fewer prescriptions for medications commonly used <a href="https://www.benzinga.com/topic/anxiety">to treat anxiety</a>, according to a recent study published in JAMA Network Open.
The findings consistently showed that increased access to marijuana correlates with reductions in benzodiazepine prescription fills, which refer to the number of prescriptions picked up by patients, not the number written by doctors. 
Lead <a href="https://spp.gatech.edu/people/person/ashley-bradford">author</a> Ashley Bradford, PhD, of the Georgia Institute of Technology, <a href="https://www.painnewsnetwork.org/stories/2025/1/19/prescriptions-for-anti-anxiety-meds-decline-in-states-where-marijuana-is-legal#google_vignette">noted</a> that the research is particularly relevant given that nearly 23% of U.S. adults reported having a diagnosable mental health disorder in 2021, but only 65% of them received treatment.
Expanding cannabis access offers an alternative treatment avenue, especially as many <a href="https://www.benzinga.com/cannabis/laws">state medical marijuana laws</a> allow patients with mental health conditions like post-traumatic stress disorder (PTSD) to use medical cannabis. The Food and Drug Administration <a href="https://www.benzinga.com/24/11/42100354/fda-approves-cannabis-trial-for-veterans-with-ptsd-after-years-of-delays">approved a clinical trial in November 2024</a> to assess the efficacy of smoked medical marijuana in treating PTSD among military veterans.
The <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823248?resultClick=3">findings</a> have significant implications for insurance providers, prescribers, patients and pharmaceutical companies that produce benzodiazepines, which, like opioids, carry risks. In 2020, benzodiazepines contributed to 14% of total opioid overdose deaths, said Bradford, who added that the substitution of marijuana for medications with high misuse potential could also have far-reaching public health benefits.
<h2 class="wp-block-heading">Could Cannabis For Anxiety Cut Into Big Pharma's Bottom Line?</h2>
Bradford&#8217;s research focused on medications like Valium, Xanax and Ativan, which are brand names for diazepam, alprazolam and lorazepam, respectively. Xanax and Lorazepam are produced by Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Wyeth Pharmaceuticals, which <a href="https://www.investopedia.com/companies-owned-by-pfizer-5211303">Pfizer acquired in 2009</a>.
The most common drug, Valium, produced by the Hoffmann-La Roche pharmaceutical company – now <a href="https://www.benzinga.com/24/12/42721437/roche-ceo-reassures-no-job-cuts-despite-drug-development-challenges-reports">Roche Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) &nbsp;&#8211; was introduced in 1963 and gained popularity as a sedative almost immediately. Between 1969 and 1982, "Mother's Little Helper" as the Rolling Stones called it in their 1966 hit song, Valium was the <a href="https://drugabuse.com/benzodiazepines/valium/history-and-statistics/">most prescribed drug in the US</a>. Sales peaked in 1978 with more than 2.3 billion pills sold that year. 
Roche, with a market value of $244.27 billion, is among the <a href="https://www.visualcapitalist.com/cp/worlds-50-largest-pharmaceutical-companies/">largest pharmaceutical companies</a> in the world.
According to <a href="https://my.clevelandclinic.org/health/treatments/24570-benzodiazepines-benzos">the</a> Cleveland Clinic, benzodiazepines are still among the most commonly prescribed medications and are notably &#8220;habit-forming.&#8221; 
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/01/43107039/elizabeth-warren-questions-robert-f-kennedy-jr-on-dangerous-views-pot-legalization-timeline-as-his-senate-hearing-stalls">Elizabeth Warren Questions Robert F. Kennedy Jr. On &#8216;Dangerous Views,&#8217; Pot Legalization Timeline As His Senate Hearing Stalls</a></li>
</ul>
Photo: Shutterstock

Cannabis

Health Care

RHHBY

Legal Marijuana Linked To Drop In Anxiety Medications: What It Means For Pharma Giants

White Mountains Insurance's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTM#NYSE">WTM</a>) short percent of float has risen 30.56% since its last report. The company recently reported that it has 46 thousand shares sold short, which is 1.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.35 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>White Mountains Insurance Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737488723_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for White Mountains Insurance has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing White Mountains Insurance's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, White Mountains Insurance's peer group average for short interest as a percentage of float is 1.94%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into White Mountains Insurance's Recent Short Interest

Kinder Morgan's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) short percent of float has fallen 4.74% since its last report. The company recently reported that it has 42.76 million shares sold short, which is 2.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Kinder Morgan Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737488719_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Kinder Morgan has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Kinder Morgan's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kinder Morgan's peer group average for short interest as a percentage of float is 4.32%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Kinder Morgan?

In a report released on October 25, Johan Sjoberg from Kepler Capital maintained a Hold rating on Epiroc AB (EPI.A – Research Report), with a price...

Kepler Capital  Remains a Hold on Epiroc AB (EPI.A)

Citi raised the firm's price target on Epiroc (EPOKY) to SEK 219 from SEK 214 and keeps a Neutral rating on the shares. Published first on TheFly –...

Epiroc price target raised to SEK 219 from SEK 214 at Citi

Warning: EPOKY is at high risk of cutting its dividend

Comments

Epiroc

Epiroc (EPOKY) Forecast

Epiroc (OTC:EPOKY) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga